Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response
Conditions
- NSCLC
- Melanoma
- Kidney Cancer
- Urothelial Carcinoma
- Head and Neck Cancer
Interventions
- OTHER: Breathprint analysis and patient-reported outcomes
Sponsor
University Health Network, Toronto
Collaborators